Provided by Tiger Trade Technology Pte. Ltd.

Plus Therapeutics, Inc.

5.95
+0.30005.31%
Post-market: 5.75-0.1999-3.36%19:53 EDT
Volume:340.86K
Turnover:1.98M
Market Cap:40.83M
PE:-0.82
High:5.98
Open:5.52
Low:5.48
Close:5.65
52wk High:30.50
52wk Low:2.90
Shares:6.86M
Float Shares:6.34M
Volume Ratio:0.44
T/O Rate:5.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.2500
EPS(LYR):-48.8611
ROE:-522.50%
ROA:-83.29%
PB:10.22
PE(LYR):-0.12

Loading ...

Plus Therapeutics names Randy Goodman vice president of value strategy, HEOR

Reuters
·
Apr 15

Press Release: Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution

Dow Jones
·
Apr 15

Plus Therapeutics names Eric Daniels chief development officer to advance clinical pipeline

Reuters
·
Apr 09

Press Release: Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline

Dow Jones
·
Apr 09

Plus Therapeutics Inc : Ascendiant Capital Markets Cuts Target Price to $65 From $475

THOMSON REUTERS
·
Apr 09

BUZZ-Plus Therapeutics rises as FDA grants orphan drug tag for pediatric brain cancer treatment

Reuters
·
Apr 08

Plus Therapeutics wins FDA orphan drug designation for REYOBIQ in pediatric malignant gliomas

Reuters
·
Apr 08

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to Reyobiq™ in Pediatric Malignant Gliomas

THOMSON REUTERS
·
Apr 08

Analysts Offer Insights on Healthcare Companies: Plus Therapeutics (PSTV) and Terns Pharmaceuticals (TERN)

TIPRANKS
·
Apr 08

Plus CNSide Cerebrospinal Fluid Tumor Cell Enumeration test gets AMA PLA code

TIPRANKS
·
Apr 07

BUZZ- Plus Therapeutics rises as it secures new billing code for cancer test

Reuters
·
Apr 07

Plus Therapeutics Receives AMA Pla Code for Cnside® Csf Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption

THOMSON REUTERS
·
Apr 07

Plus Therapeutics Inc : Maxim Group Adjusts Target Price to $12 From $37.5 to Reflect 1-for-25 Reverse Stock Split

THOMSON REUTERS
·
Apr 07

Plus Therapeutics’ treatment of malignant glioma granted FDA orphan designation

TIPRANKS
·
Apr 07

Plus Therapeutics enacts 1-for-25 reverse stock split to maintain Nasdaq listing

Reuters
·
Apr 03

Plus Therapeutics secures Highmark coverage for CNSide CSF assay, expands covered lives to 75 million

Reuters
·
Apr 02

NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM

Reuters
·
Apr 02

Plus Therapeutics enacts 1-for-25 reverse stock split to meet Nasdaq $1 bid rule

Reuters
·
Apr 01

Plus Therapeutics announces annual shareholder meeting

Reuters
·
Apr 01

Plus Therapeutics grants inducement awards: options, RSUs covering 600,000 shares

Reuters
·
Apr 01